It is very uncertain whether CHLORPROMAZINE changes adverse effects ‐ seizures compared with HALOPERIDOL (very low certainty).
It is very uncertain whether CHLORPROMAZINE changes leaving the study early compared with HALOPERIDOL (very low certainty).
Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ any reason compared with typical antipsychotics (low certainty).
It is very uncertain whether levomepromazine changes leaving the study early ‐ short term ‐ due to lack of efficacy compared with atypical antipsychotics (very low certainty).
Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ due to patient deterioration compared with atypical antipsychotics (moderate certainty).
Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ lost to compared with atypical antipsychotics (low certainty).
Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ due to lack of efficacy compared with typical antipsychotics (low certainty).
Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ due to adverse events compared with typical antipsychotics (low certainty).
It is very uncertain whether levomepromazine changes leaving the study early ‐ medium term ‐ any reason compared with typical antipsychotics (very low certainty).
Levomepromazine showed no clear difference in leaving the study early ‐ long term ‐ any reason compared with typical antipsychotics (moderate certainty).
Levomepromazine showed no clear difference in leaving the study early ‐ long term ‐ due to adverse events compared with typical antipsychotics (moderate certainty).
Levomepromazine showed no clear difference in leaving the study early ‐ long term ‐ lost to compared with typical antipsychotics (moderate certainty).
Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ any reason compared with atypical antipsychotics (low certainty).
Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ due to adverse events compared with atypical antipsychotics (moderate certainty).
SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG showed no clear difference in global state: No clinically important response ‐ short term compared with ANY ANTIPSYCHOTIC DRUG (low certainty).
It is very uncertain whether SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG changes specific adverse effects: 1a. CNS ‐ short term ‐ movement disorder ‐… compared with ANY ANTIPSYCHOTIC DRUG (very low certainty).
SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG may leads to lower specific adverse effects: 3a. Endocrine system ‐ short term ‐ weight… compared with ANY ANTIPSYCHOTIC DRUG (low certainty).
SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG may leads to lower specific adverse effects: 4. Gastrointestinal system ‐ short term ‐… compared with ANY ANTIPSYCHOTIC DRUG (low certainty).
SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG may leads to lower mental state: 1a. General ‐ No clinical important improvement ‐ BPRS… compared with ANY ANTIPSYCHOTIC DRUG (low certainty).
SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG showed no clear difference in mental state: 2a. Negative symptoms ‐ No clinical important… compared with ANY ANTIPSYCHOTIC DRUG (low certainty).